New drug HCB301 enters early human trials for tough cancers
NCT ID NCT06487624
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called HCB301 in 50 adults with advanced solid tumors or Hodgkin lymphoma that has come back or not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of shrinking tumors. Participants receive HCB301 by IV infusion, and researchers will monitor side effects and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HCB301 (a drug given by IV infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid tumors or Hodgkin lymphoma who have run out of standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 50 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects, and it is too soon to know if it will be effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
RECRUITINGKaohsiung City, Taiwan
-
Prisma Health-Upstate
RECRUITINGGreenville, South Carolina, 29605, United States
-
Southern Medical University Zhujiang Hospital
RECRUITINGZhujiang, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, China
-
Xuzhou Central Hospital
RECRUITINGXuzhou, China
-
Yantai Yuhuangding Hospital
RECRUITINGYantai, China
-
Zhejiang Provincial Cancer Hospital
RECRUITINGHangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?